Seryl-tRNA Synthetase (SARS) (AA 2-233) Antikörper (FITC)
Kurzübersicht für Seryl-tRNA Synthetase (SARS) (AA 2-233) Antikörper (FITC) (ABIN7168951)
Target
Alle Seryl-tRNA Synthetase (SARS) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
- 
    - 
                                            Bindungsspezifität
- AA 2-233
- 
                                            Kreuzreaktivität
- Human
- 
                                            Aufreinigung
- >95%, Protein G purified
- 
                                            Immunogen
- Recombinant Human Serine--tRNA ligase, cytoplasmic protein (2-233AA)
- 
                                            Isotyp
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            Beschränkungen
- Nur für Forschungszwecke einsetzbar
 
- 
                                            
- 
    - 
                                            Format
- Liquid
- 
                                            Buffer
- 
                        Preservative: 0.03 % Proclin 300
 Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4
- 
                                            Konservierungsmittel
- ProClin
- 
                                            Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            Lagerung
- -20 °C,-80 °C
- 
                                            Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
 
- 
                                            
- 
    - Seryl-tRNA Synthetase (SARS)
- 
                                            Andere Bezeichnung
- SARS
- 
                                            Hintergrund
- 
                        Background: Catalyzes the attachment of serine to tRNA(Ser) in a two-step reaction: serine is first activated by ATP to form Ser-AMP and then transferred to the acceptor end of tRNA(Ser) (PubMed:22353712, PubMed:24095058, PubMed:9431993, PubMed:26433229, PubMed:28236339). Is probably also able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec) (PubMed:9431993, PubMed:26433229, PubMed:28236339). In the nucleus, binds to the VEGFA core promoter and prevents MYC binding and transcriptional activation by MYC (PubMed:24940000). Recruits SIRT2 to the VEGFA promoter, promoting deacetylation of histone H4 at \\\'Lys-16\\\' (H4K16). Thereby, inhibits the production of VEGFA and sprouting angiogenesis mediated by VEGFA (PubMed:19423848, PubMed:19423847, PubMed:24940000). Aliases: C78314 antibody, cytoplasmic antibody, EC 6.1.1.11 antibody, FLJ36399 antibody, sarS antibody, Sars1 antibody, Serine tRNA ligase 1, cytoplasmic antibody, Serine tRNA ligase antibody, Serine--tRNA ligase antibody, serine--tRNA ligase, cytoplasmic antibody, SerRS antibody, SERS antibody, Seryl tRNA Ser/Sec synthetase antibody, Seryl tRNA synthetase antibody, Seryl tRNA synthetase cytoplasmic antibody, Seryl-tRNA Ser/Sec synthetase antibody, Seryl-tRNA synthetase antibody, seryl-tRNA synthetase, cytoplasmic antibody, Seryl-tRNA(Ser/Sec) synthetase antibody, Strs antibody, SYSC_HUMAN antibody 
- 
                                            UniProt
- P49591
 Target
- 
                    
 
                                     
                                     
                                    